Overview

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Haruhiko Fukuda
Collaborator:
Ministry of Health, Labour and Welfare, Japan
Treatments:
Rituximab